打结石的方法重庆(重庆附近有打结石的医院没有) (今日更新中)

A man convicted in the 1971 Black Liberation Army assassination of two NYPD officers will be released on parole in October, the widow and daughter of NYPD Patrolman Joseph Piagentini told Scripps station WPIX-TV.A state source confirmed the decision late Tuesday afternoon, saying 68-year-old Anthony Bottom, who now goes by Jalil Abdul Mutaqim, has been granted "an open release date of October 20, 2020 or earlier."Bottom's been in state prison since 1977, more than 43 years."I am very angry," widow Diane Piagentini said about the decision.Piagentini accused Bottom of being the most ruthless of the killers, who lured the two patrolmen, one Black and one White, to Harlem with a phony 911 call. Both NYPD officers were fathers.The three BLA members had come to New York from California specifically to assassinate police officers.When the officers responded to the housing project, they were ambushed from behind with a fusillade of bullets.Bottom shot Piagentini’s partner, 33-year-old officer Waverly Jones, first. Jones, who was Black, was shot five times."He (Bottom) shot him in the head and down his spine," Diane Piagentini recalled.Piagentini said Bottom then turned his gun on her 27-year-old husband, who had 22 bullet holes in his body when he was pronounced dead.“He (Bottom) used Joe's gun to complete the killing because they were running out of bullets," Piagentini said of her husband’s death.Two years ago, Piagentini had unsuccessfully fought the controversial release of Bottom's accomplice, Herman Bell.Parole commissioners at the time were staying true to an Executive Order from Governor Andrew Cuomo in 2011, which told the board to be "forward thinking" and focus more on a prisoner's rehabilitation instead of the original crime.During Bell's later parole hearings, he showed remorse.The third convicted killer, Albert Washington, had died in prison.Bottom has been in police custody for more than 49 years, ever since his arrest in California in August 1971. He was sent to New York State prison in 1977.A Refinery29 article published earlier this year said he was diagnosed with COVID-19 during the pandemic.A Sullivan County judge ordered a new hearing for Bottom in August. The prisoner appeared before the parole board on Sept. 11.Diane Piagentini had written to the board in August this year, begging for Bottom not to be released."He's a BLA militant," she said. "He wants to kill cops. He has not been rehabilitated."Piagentini wasn't allowed to face parole commissioners because of the ongoing COVID-19 crisis.Despite a move to release elderly prisoners during this pandemic, Piagentini said she doesn't believe that's the motivation for Bottom's release."It has nothing to do with COVID. It has nothing to do with his age."Patrolman's Benevolent Association President Patrick Lynch, issued a statement to PIX11 Tuesday evening slamming the Parole Board decision, saying laws and mandates from Governor Cuomo and the state legislature have allowed for the latest in a long line of cop killers getting released."They knew that changing the parole guidelines would unleash more vicious killers like Anthony Bottom back onto our streets," Lynch said. "They have chosen to stand with the murderers, cold-blooded assassins, and radicals bent on overthrowing our society. We have now seen 16 cop-killers released in less than three years. We will continue to see more unless New Yorkers wake up and speak out against the madness being done in their names."Bottom had joined the Black Panther Party in the late 1960s, after the assassination of civil rights leader, Dr. Martin Luther King, Jr.He believed that armed resistance was necessary to address systemic racism in society. This article was written by Mary Murphy for WPIX. 3784

INDIANAPOLIS — The U.S. Food and Drug Administration on Monday granted emergency use authorization to Eli Lilly and Company's experimental COVID-19 antibody treatment bamlanivimab.According to a statement from the company, the drug is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test who are at high risk for progressing to severe COVID-19 and/or hospitalization. Lilly said in a statement the drug should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion."This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients — adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic," David A. Ricks, Lilly's chairman and CEO, said. "The rapid development and availability of bamlanivimab could not have been achieved without the relentless work of our Lilly team, collaboration across the industry and the urgent work being done by the government to ensure appropriate allocation to patients who need it the most."The emergency use authorization is based on data from BLAZE-1, a randomized, double-blind, placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Patients treated with the drug showed reduced viral load and rates of symptoms and hospitalization, Lilly said in the statement. Infusion reactions and other allergic hypersensitivity events have been reported, Lilly said. The emergency use authorization includes a warning for hypersensitivity including anaphylaxis and infusion-related reactions.Lilly said the drug is not authorized for use in patients who are hospitalized due to COVID-19 or who require oxygen therapy due to COVID-19 or who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity."The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus," Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories, said. "We're proud of the speed with which we have been able to bring patients this therapy specifically designed to treat COVID-19. We thank those who have contributed to this medical advancement, particularly the clinical trial investigators and participants around the country." This article was written by Bob Blake for WRTV. 2906

Dr. Scott Turner does his best to treat patients with memory disorders such as dementia. While there are treatments that may temporarily help, there's no cure for dementia, which is why a new study is getting a lot of attention. The study found your daily dose of certain medications could be increasing your risk for developing dementia. “It's a pretty substantial risk and just brings to bear the thought these medications should not be used lightly,” Dr. Turner with Georgetown University Medical Center, says. The study--published in the Journal of the American Medical Association--found the risk of getting dementia increased nearly 50 percent for patients who took medication every day for at least three years to treat some of the most common conditions in older adults, including bladder control, Parkinson’s, depression and epilepsy. “This study's important because dementia is very common in older individuals, and these classes of medications are also commonly prescribed,” Dr. Turner expresses. “So, I think there will be a lot of discussions between patients and their doctors about the risks and benefits of these medications.” The study warns people not to stop taking any medication without speaking with their doctor. Alzheimer's is the most common type of dementia, which is the sixth leading cause of death in the United States. 1363

CHICAGO, Ill. – November is Alzheimer Awareness Month. And with nearly six million Americans living with the disease, healthcare providers are looking for innovative ways to treat patients. One pilot program is putting caregivers inside the mind of Alzheimer’s patients. Using a virtual reality headset and console, Amelia Williams is immersing herself into the mind of a fictional dementia patient known as “Beatriz.” Williams is a research coordinator at 472

LONDON, England – Prince Harry and his wife Meghan are taking the first steps into their new independent life thousands of miles apart. Meghan has returned to Canada, where the couple spent a six-week Christmas break out of the public eye. Meanwhile, Harry stayed in England as the royal family sought to contain the crisis sparked by the couple's decision effectively to quit as senior royals. A friend of the couple pushed back against accusations they blindsided Queen Elizabeth II with the announcement that they would be stepping back from royal duties. “It’s certainly not true to say the palace were blindsided by this,” said broadcaster Tom Bradby, who filmed revealing interviews with Harry and Meghan while they were in Africa last year, 764

来源：资阳报